Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 397–432
- Headlines
- 674
- Sources here
- 5
- Companies here
- 23
Current section
Austria Healthcare news
Chronological news
Earlier headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech
Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 …
Sharemaestro market context Price below Trend Line 52 weeks -19.9%iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?
Key Points iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total return of 80.2% but a significantly …
LLYC
mentioned
Sharemaestro market context
Trend signal active
52 weeks +73.7% · Next-week setup positive 56.3%
Eli Lilly and Company Q2 Earnings Call Highlights
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 …
LLYC
main company
Sharemaestro market context
Trend signal active
52 weeks +73.7% · Next-week setup positive 56.3%
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?
Key Points Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of …
LLYC
mentioned
Sharemaestro market context
Trend signal active
52 weeks +73.7% · Next-week setup positive 56.3%
Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week
Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] …
Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%Insider trades: Microsoft, Meta, Pfizer among notable names
[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small …
Sharemaestro market context Price above Trend Line 52 weeks +13.3%Key HIV stat over 70% leaves BofA siding with Gilead
Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was …
Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%Earnings Scoreboard: 86% of S&P 500 reporting firms top EPS estimates as 79% post Y/Y profit growth
[Rolled newspaper with the headline Quarterly Results] Zerbor S&P 500 earnings activity accelerated this week, with more than 130 index members reporting quarterly results that provided key insights into corporate margin health, spending trends, and overall macroeconomic strength. EARNINGS ROUNDUP: * BOTTOM LINE (EPS): …
Sharemaestro market context Price above Trend Line 52 weeks +13.3%The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%
Quick Read ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat. ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting …
Sharemaestro market context Price below Trend Line 52 weeks -19.9%Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed
In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …
Sharemaestro market context Price below Trend Line 52 weeks -15.5% · Next-week setup positive 58.0%Healthcare giant slashes key consultation fee to beat rivals
CVS Health (CVS) is targeting the earliest point in a customer's weight-loss drug decision: the first consultation. On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee. That is the …
Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Revenue: $5 billion, up 4.4% on an FX-neutral basis. Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year. Adjusted Gross Margin: 54.3%, down 100 basis points versus the prior year. Adjusted EPS: $3.23, up 4.9%. …
BDX
main company
Sharemaestro market context
Price above Trend Line
52 weeks -6.4% · Next-week setup negative 42.7%
Moderna (MRNA) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …
MRNA
main company
Sharemaestro market context
Trend signal active
52 weeks +108.3%
Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Medtronic (NYSE:MDT) receives expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmia treatment. The Sphere-9 catheter …
MDT
main company
Sharemaestro market context
Price above Trend Line
52 weeks -2.9%
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …
Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and …
NNO2
mentioned
Sharemaestro market context
Trend signal active
52 weeks +27.1% · Next-week setup positive 55.2%
AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …
ABBV
main company
Sharemaestro market context
Trend signal active
52 weeks +23.7%
1% Undervalued? DENTSPLY SIRONA (XRAY) As Earnings Test Its Recovery Story
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year …
XRAY
main company
Sharemaestro market context
Price above Trend Line
52 weeks -8.2%
Novo Nordisk Stock Rises After GLP-1 Antitrust Win
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …
Sharemaestro market context Trend signal active 52 weeks +27.1% · Next-week setup positive 55.2%Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …
Sharemaestro market context Price above Trend Line 52 weeks +13.3%Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …
ROGH
main company
Sharemaestro market context
Price above Trend Line
42 weeks +35.0% · Next-week setup positive 57.1%
Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …
JNJ
main company
Sharemaestro market context
Trend signal active
52 weeks +52.0%